The U.S. Food and Drug Administration (FDA) has expanded approval for insulin inhalation powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes, according to the product manufacturer’s press release. Previously, the inhaled insulin was only approved for adults. The oral inhaler device and insulin inhalation powder deliver insulin into the bloodstream through the lungs, enabling rapid absorption of insulin into systemic circulation. Marketed as Afrezza, …
Read More









